<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="en">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Crit Care</journal-id>
      <journal-id journal-id-type="iso-abbrev">Crit Care</journal-id>
      <journal-title-group>
        <journal-title>Critical Care</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1364-8535</issn>
      <issn pub-type="epub">1466-609X</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25028805</article-id>
      <article-id pub-id-type="pmc">4056443</article-id>
      <article-id pub-id-type="publisher-id">cc13805</article-id>
      <article-id pub-id-type="doi">10.1186/cc13805</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Letter</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Pharmacokinetics of anidulafungin during albumin dialysis</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes" id="A1">
          <name>
            <surname>Aguilar</surname>
            <given-names>Gerardo</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>gerardo.aguilar@uv.es</email>
        </contrib>
        <contrib contrib-type="author" id="A2">
          <name>
            <surname>Azanza</surname>
            <given-names>Jos&#xE9; Ram&#xF3;n</given-names>
          </name>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>jrazanza@unav.es</email>
        </contrib>
        <contrib contrib-type="author" id="A3">
          <name>
            <surname>S&#xE1;daba</surname>
            <given-names>Bel&#xE9;n</given-names>
          </name>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>bsadaba@unav.es</email>
        </contrib>
        <contrib contrib-type="author" id="A4">
          <name>
            <surname>Badenes</surname>
            <given-names>Rafael</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>rafael.badenes@gmail.com</email>
        </contrib>
        <contrib contrib-type="author" id="A5">
          <name>
            <surname>Ferrando</surname>
            <given-names>Carlos</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>cafeoranestesia@gmail.com</email>
        </contrib>
        <contrib contrib-type="author" id="A6">
          <name>
            <surname>Delgado</surname>
            <given-names>Carlos</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>cardelna@gmail.com</email>
        </contrib>
        <contrib contrib-type="author" id="A7">
          <name>
            <surname>Hern&#xE1;ndez</surname>
            <given-names>Javier</given-names>
          </name>
          <xref ref-type="aff" rid="I3">3</xref>
          <email>jaherla@hotmail.com</email>
        </contrib>
        <contrib contrib-type="author" id="A8">
          <name>
            <surname>Parra</surname>
            <given-names>Mar&#xED;a Asunci&#xF3;n</given-names>
          </name>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>mparravi@unav.es</email>
        </contrib>
        <contrib contrib-type="author" id="A9">
          <name>
            <surname>Puig</surname>
            <given-names>Jaume</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>jaupuig1@gmail.com</email>
        </contrib>
        <contrib contrib-type="author" id="A10">
          <name>
            <surname>Carbonell</surname>
            <given-names>Jos&#xE9; A</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>joseacarbonell19@hotmail.com</email>
        </contrib>
        <contrib contrib-type="author" id="A11">
          <name>
            <surname>Navarro</surname>
            <given-names>David</given-names>
          </name>
          <xref ref-type="aff" rid="I4">4</xref>
          <xref ref-type="aff" rid="I5">5</xref>
          <email>david.navarro@uv.es</email>
        </contrib>
        <contrib contrib-type="author" id="A12">
          <name>
            <surname>Belda</surname>
            <given-names>F Javier</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <xref ref-type="aff" rid="I5">5</xref>
          <email>fjbelda@uv.es</email>
        </contrib>
      </contrib-group>
      <aff id="I1"><label>1</label>Surgical Intensive Care Unit, Department of Anesthesiology and Intensive Care, Hospital Cl&#xED;nico Universitario de Valencia, Avenida Blasco Ibanez 17, 406010 Valencia, Spain</aff>
      <aff id="I2"><label>2</label>Department of Clinical Pharmacology, University of Navarra Clinic, Avenida P&#xED;o XII 36, 31008 Pamplona, Spain</aff>
      <aff id="I3"><label>3</label>Intensive Care Unit, Department of Anesthesiology and Intensive Care, Consorcio Hospital General Universitario de Valencia, Avenida Tres Cruces 2, 46014 Valencia, Spain</aff>
      <aff id="I4"><label>4</label>Department of Microbiology, Hospital Cl&#xED;nico Universitario de Valencia, Avenida Blasco Ibanez 17, 46010 Valencia, Spain</aff>
      <aff id="I5"><label>5</label>School of Medicine, University of Valencia, Avenida Blasco Ibanez 15, 46010 Valencia, Spain</aff>
      <pub-date pub-type="ppub">
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>31</day>
        <month>3</month>
        <year>2014</year>
      </pub-date>
      <!-- PMC Release delay is 12 months and 0 days and was based on the epub date.-->
      <pub-date pub-type="pmc-release">
        <day>31</day>
        <month>3</month>
        <year>2015</year>
      </pub-date>
      <volume>18</volume>
      <issue>2</issue>
      <fpage>422</fpage>
      <lpage>422</lpage>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2014 BioMed Central Ltd.</copyright-statement>
        <copyright-year>2014</copyright-year>
        <copyright-holder>BioMed Central Ltd.</copyright-holder>
      </permissions>
      <self-uri xlink:href="http://ccforum.com/content/18/2/422"/>
    </article-meta>
  </front>
  <body>
    <sec>
      <title/>
      <p>In the ICU setting, current guidelines recommend echinocandins as the first-line treatment for invasive candidiasis [<xref ref-type="bibr" rid="B1">1</xref>]. Albumin dialysis (AD) has been used in the ICU as supportive therapy for hepatic failure, but this technique can significantly enhance drug elimination [<xref ref-type="bibr" rid="B2">2</xref>]. We prescribed anidulafungin for suspected invasive candidiasis in a patient with severe liver failure treated with AD and measured the plasma concentrations of the drug using high-performance liquid chromatography.</p>
      <p>This study (GEF-ANI-2010-02) was approved by the local ethics committee (INCLIVA, Institute of Research, Valencia, Spain) and written informed consent was obtained from the patient&#x2019;s next of kin. An adult patient was admitted to our ICU with acute liver failure after major hepatectomy for metastasis. The patient was given anidulafungin (200&#xA0;mg loading dose on day 1, followed by 100&#xA0;mg daily) for suspected invasive candidiasis. On the fourth day, the patient developed encephalopathy and complained of increasing pruritus. AD using the Molecular Adsorbent Recirculating System (Gambro Hospal AG, Zurich, Switzerland) was therefore started while waiting for liver function to improve. Arterial blood, urine, and dialysate samples were collected at different times after the first AD session was initiated: before starting the fourth anidulafungin infusion and at 0.5, 1, 1.5, 2, 4, 6, and 8&#xA0;hours after starting the infusion. The last samples (8&#xA0;hours) were obtained when AD was finished. Anidulafungin was well tolerated without relevant adverse effects.</p>
      <p>The following pharmacokinetic parameters were calculated: area under the concentration curve from 0 to 8&#xA0;hours using the linear trapezoidal rule, and the elimination half-life with noncompartmental analysis. The values for the peak plasma concentration, the through plasma concentration, and the time to reach the peak plasma concentration were calculated from the observed values (Figure&#xA0;<xref ref-type="fig" rid="F1">1</xref>).</p>
      <fig id="F1" position="float">
        <label>Figure 1</label>
        <caption>
          <p><bold>Pharmacokinetics of anidulafungin in a patient on albumin dialysis.</bold>&#x2009;The peak plasma concentration with the 100&#xA0;mg dose on day 4 was 9.45&#xA0;mg/l. The area under the concentration curve from 0 to 8&#xA0;hours was 53.70&#xA0;hours*mg/l. The elimination half-life was 17.81&#xA0;hours.</p>
        </caption>
        <graphic xlink:href="cc13805-1"/>
      </fig>
      <p>Plasma, urine, and dialysate samples were analysed. The limit of quantification was 0.5&#xA0;mg/l. No anidulafungin levels were measurable in the ultradiafiltrate and urine samples. The peak plasma concentration with the 100&#xA0;mg dose on day 4 was 9.45&#xA0;mg/l (Figure&#xA0;<xref ref-type="fig" rid="F1">1</xref>).</p>
      <p>Only two reports regarding the use of antifungals during AD were found in the literature, demonstrating that the influence of this technique on drug elimination appeared to be negligible [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>]. We report the first pharmacokinetic study of anidulafungin during AD. Although the main limitation of our study is the enrolment of only one patient and the sampling being no more than 8&#xA0;hours, AD appears to have little influence on the pharmacokinetics of anidulafungin and an adjustment of the drug dose is probably not required. However, further research is needed to confirm our findings.</p>
    </sec>
    <sec>
      <title>Abbreviations</title>
      <p>AD: Albumin dialysis.</p>
    </sec>
    <sec>
      <title>Competing interests</title>
      <p>GA received funds for speaking at meetings organised on behalf of Astellas, Gilead, Merck Sharp and Dohme (MSD), and Pfizer. GA also received unrestricted research grants from Astellas, MSD, and Pfizer. JRA received funds for speaking at symposia organised on behalf of Pfizer, and also received unrestricted research grants from Gilead and Pfizer. DN received funds for speaking at meetings organised on behalf of Astellas, MSD, and Pfizer. DN also received unrestricted research grants from Astellas and Pfizer. The remaining authors declare that they have no competing interests.</p>
    </sec>
    <sec>
      <title>Authors' contributions</title>
      <p>GA conceived of the study, participated in its design and helped to draft the manuscript. JRA, BS and MAP carried out the pharmacokinetics study and participated in the design of the study. RB, CF, CD, JP, JAC and JH participated in the analysis and interpretation of data. DN and FJB helped to draft the manuscript and participated in the design and coordination of the study. All authors read and approved the final manuscript.</p>
    </sec>
  </body>
  <back>
    <sec>
      <title>Acknowledgements</title>
      <p>This case report was funded by Pfizer Spain.</p>
    </sec>
    <ref-list>
      <ref id="B1">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Cornely</surname>
            <given-names>OA</given-names>
          </name>
          <name>
            <surname>Bassetti</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Calandra</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Garbino</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Kullberg</surname>
            <given-names>BJ</given-names>
          </name>
          <name>
            <surname>Lortholary</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Meersseman</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Akova</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Arendrup</surname>
            <given-names>MC</given-names>
          </name>
          <name>
            <surname>Arikan-Akdagli</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Bille</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Castagnola</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Cuenca-Estrella</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Donnelly</surname>
            <given-names>JP</given-names>
          </name>
          <name>
            <surname>Groll</surname>
            <given-names>AH</given-names>
          </name>
          <name>
            <surname>Herbrecht</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Hope</surname>
            <given-names>WW</given-names>
          </name>
          <name>
            <surname>Jensen</surname>
            <given-names>HE</given-names>
          </name>
          <name>
            <surname>Lass-Fl&#xF6;rl</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Petrikkos</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Richardson</surname>
            <given-names>MD</given-names>
          </name>
          <name>
            <surname>Roilides</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Verweij</surname>
            <given-names>PE</given-names>
          </name>
          <name>
            <surname>Viscoli</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Ullmann</surname>
            <given-names>AJ</given-names>
          </name>
          <collab>ESCMID Fungal Infection Study Group</collab>
          <article-title>ESCMID Fungal Infection Study Group. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients</article-title>
          <source>Clin Microbiol Infect</source>
          <year>2012</year>
          <volume>Suppl 7</volume>
          <fpage>19</fpage>
          <lpage>37</lpage>
          <pub-id pub-id-type="pmid">23137135</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B2">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Mitzner</surname>
            <given-names>SR</given-names>
          </name>
          <article-title>Albumin dialysis: an update</article-title>
          <source>Curr Opin Nephrol Hypertens</source>
          <year>2007</year>
          <volume>16</volume>
          <fpage>589</fpage>
          <lpage>595</lpage>
          <pub-id pub-id-type="doi">10.1097/MNH.0b013e3282f0abdb</pub-id>
          <pub-id pub-id-type="pmid">18089976</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B3">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Vogelsinger</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Joannidis</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Kountchev</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Bellmann-Weiler</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Wiedermann</surname>
            <given-names>CJ</given-names>
          </name>
          <name>
            <surname>Bellmann</surname>
            <given-names>R</given-names>
          </name>
          <article-title>Pharmacokinetics of liposomal amphotericin B during extracorporeal albumin dialysis</article-title>
          <source>Artif Organs</source>
          <year>2006</year>
          <volume>30</volume>
          <fpage>118</fpage>
          <lpage>121</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1525-1594.2006.00192.x</pub-id>
          <pub-id pub-id-type="pmid">16433846</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B4">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Weiler</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Vogelsinger</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Joannidis</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Dunzendorfer</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Bellmann</surname>
            <given-names>R</given-names>
          </name>
          <article-title>Influence of albumin dialysis on pharmacokinetics of amphotericin B colloidal dispersion and amphotericin B lipid complex</article-title>
          <source>Artif Organs</source>
          <year>2011</year>
          <volume>35</volume>
          <fpage>667</fpage>
          <lpage>671</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1525-1594.2010.01111.x</pub-id>
          <pub-id pub-id-type="pmid">21668831</pub-id>
        </mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
